Metastatic breast cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 7,948 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

  NCT07405801· Hoffmann-La Roche· Source

• Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

  NCT07619534· National Cancer Institute (NCI)· Source

• A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

  NCT05306340· Genentech, Inc.· Source

• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  NCT07060807· Merck Sharp & Dohme LLC· Source

• To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

  NCT07368998· Hoffmann-La Roche· Source

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  NCT05564377· National Cancer Institute (NCI)· Source

• Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

  NCT04222413· National Cancer Institute (NCI)· Source

• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer

  NCT05104866· AstraZeneca AB· Source

• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· AstraZeneca· Source

• Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer

  NCT07706179· University of Wisconsin, Madison· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 19
• Organoids 7
• CRISPR-Cas Systems 4
• Gene Expression Profiling 61
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 5
• Proteomics 16
• Metabolomics 3
• Mass Spectrometry 1
• Flow Cytometry 9
• Immunohistochemistry 69
• Liquid Biopsy 18
• Circulating Tumor DNA 46
• Xenograft Model Antitumor Assays 109
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 62
• Machine Learning 30
• Deep Learning 23
• Cohort Studies 56
• Genome-Wide Association Study 1

See which targets of this disease your abstract mentions, and go to the people working on them.